2023 international evidence-based guideline pcos glp-1 receptor agonist The dual impact of agonists on metabolic and reproductive health in polycystic ovary syndrome: insights from human and animal trials The use of GLP-1: receptor

Commun Biol

While pipelines at companies such as Novo Nordisk and Eli Lilly dominate headlines, accelerating demand and supply chain constraints are shifting attention toward the wider ecosystem required to scale production

J Clin Endocrinol Metab (2021) 106(3):91221

Weight Loss Drug Comparison: Efficacy, Muscle Loss, and Market Stage Towards a Dual-Action Approach: Fat Loss and Muscle Preservation Recognizing the need for a more balanced approach to weight management, pharmaceutical innovators are now focusing on therapies that not only promote fat loss but also preserve or enhance muscle mass (Rodgers and Christopher 2022)

GLP-1 receptor agonists and kidney protection

*Correspondence: Qiyuan Keith Liu, [email protected]